<DOC>
	<DOCNO>NCT01020448</DOCNO>
	<brief_summary>The purpose study evaluate effect initial hormonal treatment gonadotrophin-releasing hormone ( GnRH Agonist ) 2 biomarkers ( PCA3 TMPRSS2-ERG ) , patient histologically confirm advanced stage prostate cancer . Their characteristic , accord risk factor PSA Gleason score determine baseline 1 , 3 6 month post-treatment .</brief_summary>
	<brief_title>Effect Triptorelin ( Decapeptyl® ) 22.5 mg Two Biomarkers Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>A histologically confirm , locally advanced metastatic prostate cancer , naïve androgen deprivation therapy , candidate hormonal treatment . An estimated survival time least twelve month accord investigator 's assessment . A performance status score ≤ 2 accord World Health Organisation ( WHO ) criterion . Previous surgical castration . Previous plan curative prostate cancer therapy ( radiation/surgery ) Previous hormone therapy ( GnRH analogue , estrogen antiandrogens ) Patients risk serious complication case tumour flare ( vertebral metastasis threaten spinal cord compression significant obstructive uropathy )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Locally advanced metastatic Prostate Cancer</keyword>
</DOC>